Tislelizumab synergizes with surgery to augment the survival benefit in stage II-III non-small cell lung cancer
Authors
- Linhai Zhu (ORCID: https://orcid.org/0000-0002-0433-5348)
- Wang Lv (ORCID: https://orcid.org/0009-0007-2014-0480)
- Yanye Wang (ORCID: https://orcid.org/0000-0003-3418-1332)
- Jian Hu
- Pinghui Xia
- Xuhua Huang (ORCID: https://orcid.org/0000-0002-0022-2661)
- Yiqing Wang (ORCID: https://orcid.org/0000-0002-5626-8589)
- Jia-Cong Liu
Institutions
- First Affiliated Hospital Zhejiang University (CN)
- Zhejiang University of Technology (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2024-08-31
- DOI
- https://doi.org/10.1007/s12672-024-01278-5
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- National Key Research and Development Program of China
- Science and Technology Program of Zhejiang Province